Brokerages Set Savara Inc (NASDAQ:SVRA) PT at $11.17

Shares of Savara Inc (NASDAQ:SVRA) have received an average rating of “Moderate Buy” from the six ratings firms that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $10.17.

A number of research firms have recently commented on SVRA. JMP Securities restated a “market outperform” rating and issued a $9.00 price target on shares of Savara in a report on Tuesday, October 1st. HC Wainwright lowered their price target on shares of Savara from $10.00 to $6.00 and set a “buy” rating on the stock in a report on Wednesday. Finally, Evercore ISI restated an “in-line” rating and issued a $5.00 price target (down from $7.00) on shares of Savara in a report on Wednesday.

Institutional Investors Weigh In On Savara

A number of institutional investors have recently added to or reduced their stakes in the stock. ProShare Advisors LLC grew its stake in Savara by 9.0% in the 1st quarter. ProShare Advisors LLC now owns 25,715 shares of the company’s stock valued at $128,000 after acquiring an additional 2,114 shares during the period. The Manufacturers Life Insurance Company boosted its stake in Savara by 9.0% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 44,956 shares of the company’s stock worth $191,000 after purchasing an additional 3,706 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its stake in Savara by 15.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 33,692 shares of the company’s stock worth $168,000 after purchasing an additional 4,625 shares during the last quarter. The Manufacturers Life Insurance Company boosted its stake in Savara by 14.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 41,250 shares of the company’s stock worth $166,000 after purchasing an additional 5,335 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Savara by 5.1% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 125,815 shares of the company’s stock worth $533,000 after purchasing an additional 6,141 shares during the last quarter. Institutional investors and hedge funds own 87.93% of the company’s stock.

Savara Price Performance

SVRA stock opened at $3.19 on Tuesday. Savara has a one year low of $3.09 and a one year high of $5.70. The company’s fifty day moving average price is $3.93 and its 200-day moving average price is $4.21. The company has a debt-to-equity ratio of 0.26, a quick ratio of 11.31 and a current ratio of 11.31. The company has a market capitalization of $525.08 million, a PE ratio of -7.60 and a beta of 1.02.

Savara (NASDAQ:SVRA) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.11) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.11). On average, equities analysts anticipate that Savara will post -0.44 EPS for the current fiscal year.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.